Terms: = Germ cell tumor AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
375 results:
1. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
2. [Systemic treatment of adult gliomas: a narrative review].
Mangel L
Magy Onkol; 2024 Mar; 68(1):67-75. PubMed ID: 38484377
[TBL] [Abstract] [Full Text] [Related]
3. Zeaxanthin impairs angiogenesis and tumor growth of glioblastoma: An in vitro and in vivo study.
Lu F; Wu Q; Lei J; Zhou Y; Liu Y; Zhu N; Yu Y; Lin L; Hu M
Arch Biochem Biophys; 2024 Apr; 754():109957. PubMed ID: 38467357
[TBL] [Abstract] [Full Text] [Related]
4. Transmembrane modification of tumor vascular targeting peptide A7R as molecular cargo delivery tool.
Zhang Q; Yang Z; Zhang J; Li Y; Dang X; Qu J; Pan X; Zhang J
Bioorg Chem; 2024 Apr; 145():107240. PubMed ID: 38412651
[TBL] [Abstract] [Full Text] [Related]
5. Decoding the synergistic potential of MAZ-51 and zingerone as therapy for melanoma treatment in alignment with sustainable development goals.
Letsoalo K; Nortje E; Patrick S; Nyakudya T; Hlophe Y
Cell Biochem Funct; 2024 Mar; 42(2):e3950. PubMed ID: 38348768
[TBL] [Abstract] [Full Text] [Related]
6. Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.
Zhao S; Zhang M; Zhang Q; Wu J; Dai H
BMC Cancer; 2024 Jan; 24(1):6. PubMed ID: 38166698
[TBL] [Abstract] [Full Text] [Related]
7. m5C modification of LINC00324 promotes angiogenesis in glioma through CBX3/vegfr2 pathway.
Pan A; Xue Y; Ruan X; Dong W; Wang D; Liu Y; Liu L; Lin Y; E T; Lin H; Xu H; Liu X; Wang P
Int J Biol Macromol; 2024 Feb; 257(Pt 1):128409. PubMed ID: 38016610
[TBL] [Abstract] [Full Text] [Related]
8. Dual targeting of DR5 and vegfr2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesis.
Isakova AA; Artykov AA; Plotnikova EA; Trunova GV; Khokhlova VА; Pankratov AA; Shuvalova ML; Mazur DV; Antipova NV; Shakhparonov MI; Dolgikh DA; Kirpichnikov MP; Gasparian ME; Yagolovich AV
Int J Biol Macromol; 2024 Jan; 255():128096. PubMed ID: 37972835
[TBL] [Abstract] [Full Text] [Related]
9. STING activation counters glioblastoma by vascular alteration and immune surveillance.
Joseph JV; Blaavand MS; Cai H; Vernejoul F; Knopper RW; Lindhardt TB; Skipper KA; Axelgaard E; Reinert L; Mikkelsen JG; Borghammer P; Degn SE; Perouzel E; Hager H; Hansen B; Kalucka JM; Vendelbo M; Paludan SR; Thomsen MK
Cancer Lett; 2023 Nov; 579():216480. PubMed ID: 37931834
[TBL] [Abstract] [Full Text] [Related]
10. Network pharmacology-based strategy to investigate the effect and mechanism of α-solanine against glioma.
Wang C; Liu X; Guo S
BMC Complement Med Ther; 2023 Oct; 23(1):371. PubMed ID: 37865727
[TBL] [Abstract] [Full Text] [Related]
11. Pseudogene MAPK6P4-encoded functional peptide promotes glioblastoma vasculogenic mimicry development.
Zhang M; Zhao Y; Liu X; Ruan X; Wang P; Liu L; Wang D; Dong W; Yang C; Xue Y
Commun Biol; 2023 Oct; 6(1):1059. PubMed ID: 37853052
[TBL] [Abstract] [Full Text] [Related]
12. Gestational choriocarcinoma.
Bogani G; Ray-Coquard I; Mutch D; Vergote I; Ramirez PT; Prat J; Concin N; Ngoi NYL; Coleman RL; Enomoto T; Takehara K; Denys H; Lorusso D; Takano M; Sagae S; Wimberger P; Segev Y; Kim SI; Kim JW; Herrera F; Mariani A; Brooks RA; Tan D; Paolini B; Chiappa V; Longo M; Raspagliesi F; Benedetti Panici P; Di Donato V; Caruso G; Colombo N; Pignata S; Zannoni G; Scambia G; Monk BJ
Int J Gynecol Cancer; 2023 Oct; 33(10):1504-1514. PubMed ID: 37758451
[TBL] [Abstract] [Full Text] [Related]
13. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F; Brizzi MP; Amoroso V; Giuffrida D; Panzuto F; Campana D; Prinzi N; Milione M; Cascella T; Spreafico C; Randon G; Oldani S; Leporati R; Scotto G; Pulice I; Stocchetti BL; Porcu L; Coppa J; Di Bartolomeo M; de Braud F; Pusceddu S
BMC Cancer; 2023 Sep; 23(1):908. PubMed ID: 37752423
[TBL] [Abstract] [Full Text] [Related]
14. Molecular mechanism of lycorine in the treatment of glioblastoma based on network pharmacology and molecular docking.
Su J; Huo M; Xu F; Ding L
Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1551-1559. PubMed ID: 37668687
[TBL] [Abstract] [Full Text] [Related]
15. PDGFRA, KIT, and kdr Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance.
Carlotto BS; Trevisan P; Provenzi VO; Soares FP; Rosa RFM; Varella-Garcia M; Zen PRG
Neuromolecular Med; 2023 Sep; 25(3):441-450. PubMed ID: 37610648
[TBL] [Abstract] [Full Text] [Related]
16. In vitro evaluation of Axitinib and Sorafenib treatment in glioblastoma cell viability and morphology.
Opriţa A; Dobrescu MA; Manea EV; Popescu ŞO; Sevastre AS; Pîrvu AS; Buzatu IM; Tache DE
Rom J Morphol Embryol; 2023; 64(2):173-180. PubMed ID: 37518874
[TBL] [Abstract] [Full Text] [Related]
17. Targeting glioblastoma multiforme using a novel fusion protein comprising interleukin-13 and staphylococcal enterotoxin B in vitro.
Gholipour Z; Fooladi AAI; Parivar K; Halabian R
Toxicol In Vitro; 2023 Oct; 92():105651. PubMed ID: 37482138
[TBL] [Abstract] [Full Text] [Related]
18. The role of immune subtyping in glioma mRNA vaccine development.
Guterres A; Abrahim M; da Costa Neves PC
Immunotherapy; 2023 Sep; 15(13):1057-1072. PubMed ID: 37431617
[TBL] [Abstract] [Full Text] [Related]
19. A novel peptide P1-121aa encoded by STK24P1 regulates vasculogenic mimicry via ELF2 phosphorylation in glioblastoma.
Li T; Liu X; Ruan X; Dong W; Liu Y; Wang P; Liu L; Tiange E; Song J; Pan A; Xue Y
Exp Neurol; 2023 Sep; 367():114477. PubMed ID: 37406957
[TBL] [Abstract] [Full Text] [Related]
20. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract] [Full Text] [Related]
[Next]
